| Company | Role | Class | Num Shares | Value | Price $ | Report Date | Ownership |
|---|---|---|---|---|---|---|---|
| Trevi Therapeutics, Inc. | Director | Nonstatutory Stock Option (right to buy) | 45,000 | 11 Jun 2025 | Direct | ||
| APPLIED GENETIC TECHNOLOGIES CORP | Director | Stock Option (Right to Buy) | 0 | 30 Nov 2022 | Direct |
| Symbol | Company | Period | Transactions | Value $ | Form Type | Role | Filing Time |
|---|---|---|---|---|---|---|---|
| TRVI | Trevi Therapeutics, Inc. | 11 Jun 2025 | 1 | $0 | 4 | Director | 13 Jun 2025, 16:00 |
| TRVI | Trevi Therapeutics, Inc. | 13 Jun 2024 | 1 | $0 | 4 | Director | 14 Jun 2024, 16:30 |
| TRVI | Trevi Therapeutics, Inc. | 28 Jun 2023 | 1 | $0 | 4 | Director | 30 Jun 2023, 16:00 |
| /report/000120919123000214-vanlent-anne-2023-01-01 | ObsEva SA | 01 Jan 2023 | 0 | $0 | 3 | Director | 03 Jan 2023, 15:27 |
| /report/000106299322023029-vanlent-anne-2022-11-30 | APPLIED GENETIC TECHNOLOGIES CORP | 30 Nov 2022 | 7 | $0 | 4 | Director | 01 Dec 2022, 08:23 |
| TRVI | Trevi Therapeutics, Inc. | 23 Jun 2022 | 1 | $0 | 4/A | Director | 01 Jul 2022, 16:59 |
| /report/000106299321012061-vanlent-anne-2021-11-30 | APPLIED GENETIC TECHNOLOGIES CORP | 30 Nov 2021 | 1 | $0 | 4 | Director | 02 Dec 2021, 18:00 |
| TRVI | Trevi Therapeutics, Inc. | 16 Jun 2021 | 1 | $0 | 4 | Director | 17 Jun 2021, 16:01 |